96 related articles for article (PubMed ID: 38496877)
1. Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer.
Liang X; Xu J; Jiang Y; Yan Y; Wu H; Dai J; Cui Y; Zhang C; Chen W; Zhang Z; Guo R
Mol Carcinog; 2024 Jun; ():. PubMed ID: 38860603
[TBL] [Abstract][Full Text] [Related]
2. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
3. Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer.
Bai H; Zhou Y; Liu W; Xu WY; Cheng L; Huo Y; Ji H; Xiong L
Heliyon; 2024 Mar; 10(6):e27633. PubMed ID: 38496877
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations predict poor efficacy, outcomes and resistance to second-line osimertinib treatment in non-small cell lung cancer.
Bai H; Cheng L; Liu W; Xu WY; Huo Y; Diao L; Ji H; Xiong L
Am J Cancer Res; 2024; 14(1):33-51. PubMed ID: 38323283
[TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
6. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
7. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
9. A Real-World Molecular Epidemiological Study of Non-Small-Cell Lung Cancer (NSCLC) Patients from Western India.
Joshi A; Korgavkar R; Joshi K; Maniar V; Kalaskar P; Kendre P; Maheshwari UD; Pethe C; Sheth S; Dhande S
South Asian J Cancer; 2023 Jul; 12(3):263-265. PubMed ID: 38047052
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
11. Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort.
Shen F; Guo W; Song X; Wang B
Diagn Pathol; 2023 Jun; 18(1):71. PubMed ID: 37301854
[TBL] [Abstract][Full Text] [Related]
12. The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer.
Choudhury NJ; Lavery JA; Brown S; de Bruijn I; Jee J; Tran TN; Rizvi H; Arbour KC; Whiting K; Shen R; Hellmann M; Bedard PL; Yu C; Leighl N; LeNoue-Newton M; Micheel C; Warner JL; Ginsberg MS; Plodkowski A; Girshman J; Sawan P; Pillai S; Sweeney SM; Kehl KL; Panageas KS; Schultz N; Schrag D; Riely GJ;
Clin Cancer Res; 2023 Sep; 29(17):3418-3428. PubMed ID: 37223888
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance.
Wang M; Zhao J; Chen T; Hu X; Wang L; Shi Y; Liu Y
Thorac Cancer; 2023 Apr; 14(10):873-880. PubMed ID: 36843208
[TBL] [Abstract][Full Text] [Related]
14. EGFR Mutation in Non-squamous Non-small-cell Lung Carcinoma (NS-NSCLC) in the Arab World: A systematic Review.
Nassar D; Chidiac C; Ibrahim E; Abou Zeid K; Haddad F; Kourie H
Gulf J Oncolog; 2023 Jan; 1(41):54-61. PubMed ID: 36804159
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
